Biopharmaceutical
Pharmaceutical
Medical

Gilead Sciences

17,997

$70.25
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$2.80 (-3.84%) Today
+$0.15 (+0.21%) As of 4:52 PM EST after-hours

Why Robinhood?

You can buy or sell GILD and other stocks, options, ETFs, and crypto commission-free!

About GILD

Gilead Sciences, Inc. Common Stock, also called Gilead Sciences, is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Read More Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

CEO
Daniel O'Day
Employees
11,000
Headquarters
Foster City, California
Founded
1987
Market Cap
84.82B
Price-Earnings Ratio
16.52
Dividend Yield
3.90
Average Volume
18.70M
High Today
$73.85
Low Today
$69.02
Open Price
$73.72
Volume
38.58M
52 Week High
$74.52
52 Week Low
$60.89

Collections

Biopharmaceutical
Pharmaceutical
Medical
Biotechnology
Health
Research And Development
Therapy
Technology

GILD News

BenzingaFeb 24

PreMarket Prep Stock Of The Day: Gilead Sciences

Benzinga's PreMarket Prep airs every morning from 8-9:00 a.m. EST. During that fast-paced highly informative hour, traders and investors tune in to get the majo
378
BloombergFeb 24

Gilead Surges After WHO Comments on Coronavirus Drug Testing

(Bloomberg) -- Gilead Sciences Inc. shares gained Monday after a senior World Health Organization official said the company’s experimental drug may be the best
2,511
ReutersFeb 19

BRIEF-Gilead Appoints Michael Quigley To Lead Research Biology Group

Feb 19 (Reuters) - Gilead Sciences Inc: * GILEAD APPOINTS MICHAEL QUIGLEY TO LEAD RESEARCH BIOLOGY GROUP AND NAMES LINDA HIGGINS AS HEAD OF COMPANY’S EXTERNAL
611

GILD Earnings

$0.00
$0.64
$1.27
$1.91
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
— per share
Actual
Expected Apr 30, After Hours

People Also Bought

Bristol-Myers Squibb

7,781

$62.14

-2.86%

Bristol-Myers Squibb

7,781

$62.14

-2.86%

AbbVie

27,048

$89.01

-4.43%

Bristol-Myers Squibb Comp...

$3.52

-3.55%

Pfizer

34,293

$33.95

-2.08%

CVS

22,704

$64.34

-5.27%

Wells Fargo

17,222

$45.12

-2.74%

AT&T

105,249

$37.39

-1.74%

Exxon Mobil

25,111

$54.25

-3.74%

Johnson & Johnson

21,716

$144.65

-0.86%

IBM

12,786

$141.71

-3.22%

Amgen

2,372

$211.59

-2.89%

GM

38,314

$31.75

-4.05%

You May Also Like

CACI
QHC
TTEK
STCN
IIF
TEUM
AIRTW
CRM
IEIH
SYNL
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.

Buy GILD

Market Price$70.25
Commissions$0.00
Estimated Cost
$0.00
Sign up for a Robinhood Account to buy or sell GILD stock and options commission-free.
Search
LearnBlogCareersHelpLog InSign Up